Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Madrigal Pharmaceuticals (MDGL) announced on Friday an exclusive global license agreement with Pfizer (PFE) for ervogastat, ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Cheese is one of the few foods that can start a family argument without anyone leaving the kitchen and lately, it has managed ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer Inc. is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people familiar with the matter.

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...